The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...

Duchenne Muscular Dystrophy: diagnosis, clinical development and global researchMuscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Founded in 2019, Epic’s technology is built on CRISPR-based discoveries from ... If EPI-321 succeeds in clinical trials, it would be a boon for people with FSHD. Symptoms of the disease start ...

A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon Athletica founder Chip Wilson — to push a next-generation CRISPR drug ...